1
Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration
Condition(s):HealthyLast Updated:December 2, 2011Completed
HYLENEX Recombinant: 30 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
Condition(s):Type 1 Diabetes MellitusLast Updated:November 7, 2018Completed
3
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
Condition(s):HealthyLast Updated:January 24, 2014Completed
4
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
Condition(s):Dermal FillerLast Updated:May 16, 2017Completed
5
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
Condition(s):Type 1 Diabetes MellitusLast Updated:February 1, 2019Completed
6
Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children
Condition(s):DehydrationLast Updated:December 1, 2011Completed
7
Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients
Condition(s):Pain ManagementLast Updated:February 28, 2014Completed
8
dMAbs for Prevention of COVID-19
Condition(s):Healthy VolunteersLast Updated:June 1, 2022Recruiting
9
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Condition(s):Healthy VolunteersLast Updated:June 13, 2022Active, not recruiting
10
Peripheral Modulation of Muscle Stiffness and Spasticity
Condition(s):Muscle SpasticityLast Updated:January 11, 2022Recruiting